[
    {
        "file_name": "DovaPharmaceuticalsInc_20181108_10-Q_EX-10.2_11414857_EX-10.2_Promotion Agreement.txt",
        "perturbation": [
            {
                "type": "Inconsistencies - Legal Contradiction",
                "original_text": "Within [***] following the end of each Calendar Quarter during the Term, Valeant shall provide Dova with a written report (each a \"Detail Report\"), setting out (i) the quarterly average number of Sales Representatives during such Calendar Quarter (calculated by taking the sum of the number of Sales Representatives employed by Valeant (or its affiliates) that have incentive compensation packages that comply with the terms of Section 4.1.3 on each Business Day of the Calendar Quarter divided by the number of Business Days in such Calendar Quarter) (the \"Quarterly Average Sales Force Size\"), and (ii) the aggregate actual number of Details for the Product made by its Sales Representatives during such Calendar Quarter, and the number of Details broken down by the name of the Target Professionals,. Through the JSC, the Parties shall agree on a mutually acceptable form of Detail Report.",
                "changed_text": "Within [***] following the end of each Calendar Quarter during the Term, Valeant shall provide Dova with a written report (each a \"Detail Report\"), setting out (i) the quarterly average number of Sales Representatives during such Calendar Quarter (calculated by taking the sum of the number of Sales Representatives employed by Valeant (or its affiliates) that have incentive compensation packages that comply with the terms of Section 4.1.3 on each Business Day of the Calendar Quarter divided by the number of Business Days in such Calendar Quarter) (the \"Quarterly Average Sales Force Size\"), and (ii) the aggregate actual number of Details for the Product made by its Sales Representatives during such Calendar Quarter, and the number of Details broken down by the name of the Target Professionals,. Such report can be delivered within a reasonable time, as determined solely by Valeant. Through the JSC, the Parties shall agree on a mutually acceptable form of Detail Report.",
                "explanation": "By giving Valeant the power to deliver the report at their discretion, it contradicts laws for business and payment regulations.",
                "contradicted_law": "29 CFR § 516.2",
                "law_citation": "29 CFR § 516.2",
                "law_url1": [
                    "https://www.ecfr.gov/current/title-29/subtitle-B/chapter-V/subchapter-A/part-516/section-516.2"
                ],
                "law_url2": [
                    "https://www.law.cornell.edu/cfr/text/29/516.2"
                ],
                "law_explanation": "29 CFR § 516.2(a) mandates employers to maintain accurate records of hours worked and wages paid. By allowing Valeant to deliver reports at its own discretion, the modification introduces potential non-compliance. Without set timelines, Dova may be unable to properly track payment obligations related to these reports. It is expected that the Department of Labor requires these documents to be readily accessible.",
                "location": "4.2.2 Records and Reports."
            },
            {
                "type": "Inconsistencies - Legal Contradiction",
                "original_text": "Each Party agrees that, during the Term and for a period of [***] thereafter, it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement (which includes the exercise of its rights or performance of any obligations hereunder) any Confidential Information furnished to it by or on behalf of the other Party pursuant to this Agreement, except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties.",
                "changed_text": "Each Party agrees that, during the Term and for a period of 6 months thereafter, it shall keep confidential and shall not publish or otherwise disclose and shall not use for any purpose other than as provided for in this Agreement (which includes the exercise of its rights or performance of any obligations hereunder) any Confidential Information furnished to it by or on behalf of the other Party pursuant to this Agreement, except to the extent expressly authorized by this Agreement or otherwise agreed in writing by the Parties.",
                "explanation": "Reducing the confidentiality period to 6 months may conflict with trade secret protection laws that require maintaining confidentiality for an appropriate duration to preserve trade secret status.",
                "contradicted_law": "18 U.S. Code § 1836",
                "law_citation": "18 U.S. Code § 1836",
                "law_url1": [
                    "https://uscode.house.gov/view.xhtml?req=granuleid%3AUSC-prelim-title18-section1836&edition=prelim"
                ],
                "law_url2": [
                    "https://www.law.cornell.edu/topn/economic_espionage_act_of_1996"
                ],
                "law_explanation": "18 U.S. Code § 1836 addresses the protection of trade secrets. The modification introduces a legal risk because a six-month confidentiality period may be insufficient to protect trade secrets, depending on the nature of the information. A short confidentiality period could lead to the loss of trade secret status if the information becomes publicly known after this period, thereby failing to maintain the secrecy required for trade secret protection.",
                "location": "9.1 Confidentiality"
            },
            {
                "type": "Inconsistencies - Legal Contradiction",
                "original_text": "Valeant shall direct to Dova any unsolicited requests for off-label medical information from health care professionals with respect to the Product promptly following receipt by Valeant (but in no event later than [***] after receipt). Dova shall, within [***] following receipt of any such request from Valeant, address any such requests directly.",
                "changed_text": "Valeant shall direct to Dova any unsolicited requests for off-label medical information from health care professionals with respect to the Product when reasonably possible. Dova shall address any such requests directly at its convenience.",
                "explanation": "Changing from specified to indeterminate timeframes contradicts requirements for accurate and timely medical information dissemination.",
                "contradicted_law": "21 CFR § 201.100",
                "law_citation": "21 CFR § 201.100",
                "law_url1": [
                    "https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-B/section-201.100"
                ],
                "law_url2": [
                    "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/frequently-asked-questions-about-medical-product-communications-firms"
                ],
                "law_explanation": "21 CFR § 201.100(d) relates to the dissemination of off-label use information. Modifying 'promptly' and 'within [***]' to 'when reasonably possible' and 'at its convenience' weakens obligations for timely medical information dissemination. The modification makes compliance uncertain, which could be non-compliant with regulations emphasizing accurate, balanced, and scientifically sound responses to inquiries about off-label uses.",
                "location": "5.5 Unsolicited Requests for Medical Information"
            }
        ]
    }
]